The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring

GenoSaber

Status: Unknown

Conditions: Non-small-cell Lung Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT02647164

CTC2015-01

Details and patient eligibility

About

The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The time of CTC and carcinoembryonic antigen(CEA) detection is baseline, 2~7 days, 3 months, 6 months, 12 months, 24 months, 36 months after the surgery. And the time of CT detection is 6 months, 12 months, 24 months, 36 months after the surgery.

Enrollment: 360 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-80 years old
• Patients with histologically documented (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer.
• Patients will undergo surgery.
• Patients with preoperative CTCs ≥8.5 Units / 3 ml
• Informed consent must be obtained from all patients prior to beginning therapy. Patients should have the ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• Patients with histologically documented not (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer.
• After the operation review, patients' result of CTC, CT and tumor markers is incomplete at the same point.
• The blood sample isn't collected in predetermined time.
• The blood samples appear hemolysis.
• The blood sample isn't enough.